Table 1.

Assessment criteria for methodological quality of studies

Study scoring criteria
Measures for outcome: 1. Assessment tool used for oxaliplatin-induced toxicity is described 2. A description of oxaliplatin administration given (regimen, dose modification criteria) 3. Acute neuropathy assessment is described
Study population: 4. A description of baseline variables at least two is included (age, sex, cancer, stage) 5. Inclusion and exclusion criteria are described 6. Time of acute oxaliplatin-induced toxicity measurement and number of patients assessed are described between the initiation of infusion and day 14. 7. Information is given about study subject selection process criteria
Study design: 8. The study sample size is described 9. The data is prospectively gathered 10. The process of data collection is described
Results: 11. Acute toxicities are described 12. The cycle at which acute toxicity occurred is described 13. The number of patients who needed prolonged infusion and/ or dose modification due to acute toxicity described. 14. The number of patients who needed treatment delay and/ or cessation due to acute toxicity reported.

Criteria modified from [39]